Tuberculosis treatment outcome in Cameroon: a systematic review and meta-analysis
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Tuberculosis (TB) remains a major public health challenge in Cameroon, yet national evidence on treatment outcomes across the full spectrum of routine care is limited. This systematic review and meta-analysis estimated pooled proportions of treatment success, mortality, treatment failure and loss to follow-up (LTFU) among TB patients in Cameroon, and identified predictors of unfavorable outcomes.
Methods
PubMed, Embase, Scopus, Web of Science, African Journals Online and the Cochrane Library were searched, supplemented by Google Scholar and reference-list screening. Observational studies conducted in Cameroon reporting at least one WHO-defined treatment outcome were eligible. Pooled proportions and adjusted odds ratios (AOR) were estimated with random-effects models meta-analysis. Data were analyzed using R Statistics version 4.6.1.
Results
Thirty-two studies (25 cohorts, 7 cross-sectional), conducted between 1998 and 2022 across six of Cameroon’s ten regions, were included. Pooled treatment success was 78.2% (95% CI: 73.8–82.1; 27 reports; 71,784 participants; I² = 98.2%), mortality 8.1% (95% CI: 5.5–11.7; 25 reports; 71,870 participants; I² = 97.8%), treatment failure 0.9% (95% CI: 0.5–1.4; 26 reports; 71,389 participants; I² = 89.1%) and LTFU 6.8% (95% CI: 5.0–9.1; 26 reports; 70,768 participants; I² = 98.6%). Mortality was highest in the South-West (16.2%) and among TB/HIV-coinfected patients (30.5%), and lowest among children (5.0%). Treatment success was lowest in the Littoral (71.1%) and among TB/HIV-coinfected patients (60.8%) and highest among multidrug-resistant TB (89.3%) and pediatric patients (86.8%). Treatment failure significantly declined from 2.9% before 2005 to 0.5% from 2020 onward ( p < 0.001). Significant predictors of unfavorable outcomes were HIV positivity (AOR = 2.57; 95% CI: 1.86–3.55), previous TB treatment (AOR = 1.99; 95% CI: 1.40–2.84), male sex (AOR = 1.67; 95% CI: 1.45–1.92), age ≤40 years (AOR = 1.45; 95% CI: 1.06–1.98) and absence of antiretroviral therapy (AOR = 1.71; 95% CI: 1.15–2.54).
Conclusions
TB treatment outcomes in Cameroon remain suboptimal, with nearly one in five patients not achieving treatment success and high mortality among TB/HIV-coinfected individuals. Strengthening TB/HIV service integration, early antiretroviral therapy initiation, targeted support for previously treated patients and men, and improved retention in care are needed.
Systematic review registration number
CRD420261404490